Skip Nav Destination
Issues
1 October 2008
-
Cover Image
Cover Image
Immunocytochemistry and confocal microscopy of parental CCRF-CEM and 2ME2-resistant leukemia cells demonstrating differences in their microtubule networks. Parental CCRF-CEM (A) and CEM/2ME2-28.8R (B) cells were cytospun onto glass slides and double-immunofluorescent detection performed for α-tubulin (green, panel ii) and acetylated α-tubulin (red, panel iii). Channels for α-tubulin and acetylated α-tubulin were overlayed and demonstrate that 2ME2-resistant cells (B, panel iii) have a denser microtubule network compared to parental cells (A, panel iii). Scale bar, represents 10 μm (B, panel iv). Location of four β-tubulin mutated residues, Asn25, Asn197, Thr248, and Asn350 in the αβ-tubulin heterodimer relative to the known colchicine-binding site identified in 2ME2-resistant leukemia cells. The locations of the mutated residues are shown in green. Blue and orange ribbons represent β- and α-tubulin, respectively. Thr248 and Asn350 mutations are situated in close proximity to the colchicine-binding site whereas Asn197 and Asn25 mutations are distinctly remote from the colchicine-binding site. For details, see Liaw et al., in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Spotlight on Molecular Profiling
Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines
Philip L. Lorenzi; Jenny Llamas; Michele Gunsior; Laurent Ozbun; William C. Reinhold; Sudhir Varma; Helen Ji; Hijoo Kim; Amy A. Hutchinson; Elise C. Kohn; Paul K. Goldsmith; Michael J. Birrer; John N. Weinstein
Review
Research Articles: Therapeutics, Targets, and Development
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors
Leslie S. Kurtzberg; Traci Battle; Cecile Rouleau; Rebecca G. Bagley; Naoki Agata; Min Yao; Steven Schmid; Stephanie Roth; Jennifer Crawford; Roy Krumbholz; Reginald Ewesuedo; Xian-Jie Yu; Fei Wang; Edmond J. LaVoie; Beverly A. Teicher
Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts
Jay Sarup; Pei Jin; Lisa Turin; Xiaomei Bai; Malgorzata Beryt; Cathleen Brdlik; Jeffrey N. Higaki; Brett Jorgensen; Francis W. Lau; Peter Lindley; Jim Liu; Irene Ni; James Rozzelle; Rajendra Kumari; Susan A. Watson; Juan Zhang; H. Michael Shepard
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Scott Ackler; Yu Xiao; Michael J. Mitten; Kelly Foster; Anatol Oleksijew; Marion Refici; Sally Schlessinger; Baole Wang; Sanjay R. Chemburkar; Joy Bauch; Christin Tse; David J. Frost; Stephen W. Fesik; Saul H. Rosenberg; Steven W. Elmore; Alex R. Shoemaker
Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer
Dongweon Song; Raghothama Chaerkady; Aik Choon Tan; Elena García-García; Anuradha Nalli; Ana Suárez-Gauthier; Fernando López-Ríos; Xian Feng Zhang; Anna Solomon; Jeffrey Tong; Margaret Read; Christian Fritz; Antonio Jimeno; Akhilesh Pandey; Manuel Hidalgo
Coronarin D, a labdane diterpene, inhibits both constitutive and inducible nuclear factor-κB pathway activation, leading to potentiation of apoptosis, inhibition of invasion, and suppression of osteoclastogenesis
Ajaikumar B. Kunnumakkara; Haruyo Ichikawa; Preetha Anand; Chiramel J. Mohankumar; Padmanabhan S. Hema; Mangalam S. Nair; Bharat B. Aggarwal
Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines
Azhar R. Hussain; Maqbool Ahmed; Naif A. Al-Jomah; Asma S. Khan; Pulicat Manogaran; Mehar Sultana; Jehad Abubaker; Leonidas C. Platanias; Khawla S. Al-Kuraya; Shahab Uddin
Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism
Sonia Priego; Fatima Feddi; Paula Ferrer; Salvador Mena; María Benlloch; Angel Ortega; Julian Carretero; Elena Obrador; Miguel Asensi; José M. Estrela
Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma
François Lamoureux; Gaëlle Picarda; Julie Rousseau; Clothilde Gourden; Séverine Battaglia; Céline Charrier; Bruno Pitard; Dominique Heymann; Françoise Rédini
Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments
Jie Gao; Geng Kou; Huaiwen Chen; Hao Wang; Bohua Li; Ying Lu; Dapeng Zhang; Shuhui Wang; Sheng Hou; Weizhu Qian; Jianxin Dai; Jian Zhao; Yanqiang Zhong; Yajun Guo
Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition
Hendrik Fischer; Ninon Taylor; Sigrid Allerstorfer; Michael Grusch; Gudrun Sonvilla; Klaus Holzmann; Ulrike Setinek; Leonilla Elbling; Heidelinde Cantonati; Bettina Grasl-Kraupp; Christine Gauglhofer; Brigitte Marian; Michael Micksche; Walter Berger
Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma
Cathy A. Payne; Sanaz Maleki; Marinella Messina; Maree G. O'Sullivan; Glenn Stone; Nathan R. Hall; Jonathon F. Parkinson; Helen R. Wheeler; Raymond J. Cook; Michael T. Biggs; Nicholas S. Little; Charles Teo; Bruce G. Robinson; Kerrie L. McDonald
Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines
Giulio Francia; Urban Emmenegger; Christina R. Lee; Yuval Shaked; Christopher Folkins; Miriam Mossoba; Jeffrey A. Medin; Shan Man; Zhenping Zhu; Larry Witte; Robert S. Kerbel
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.